左旋多巴联合卒中康复治疗:ESTREL随机临床试验
ESTREL为双盲安慰剂对照随机临床试验,在瑞士13个卒中单元和11个康复中心纳入610例急性缺血或出血性卒中伴临床意义偏瘫患者,随机接受左旋多巴/卡比多巴(100 mg/25 mg,每日3次,共39天)或安慰剂,联合标准化康复。3个月时FMA总分组间平均差异为-0.90分(95%CI,-3.78至1.98;P=0.54),左旋多巴未显著改善运动功能。
要点
- 急性卒中住院康复患者中,左旋多巴联合标准化康复与安慰剂相比未显著改善3个月运动功能。
- 3个月时FMA总分平均差异为-0.90分(95%CI,-3.78至1.98;P=0.54)。
- 左旋多巴组严重不良事件126例,安慰剂组129例,最常见为感染(左旋多巴组55例,安慰剂组44例)。
核心结论
- 在接受住院康复的急性卒中患者中,左旋多巴联合标准化康复与安慰剂联合标准化康复相比未显著改善3个月运动功能。
- 这些结果不支持使用左旋多巴作为康复治疗的辅助手段以增强急性卒中后运动恢复。
研究设计与样本
- 双盲、安慰剂对照随机临床试验,在瑞士13个卒中单元和中心及11个合作康复中心开展。
- 2019年6月14日(首例患者首次访视)至2024年8月27日(末例患者末次访视)期间,纳入610例急性缺血或出血性卒中伴临床意义偏瘫患者。
- 临床意义偏瘫定义为美国国立卫生研究院卒中量表以下项目总分≥3分:上肢运动、下肢运动或肢体共济失调。
- 患者按1:1随机接受左旋多巴/卡比多巴(100 mg/25 mg,n=307)或安慰剂(n=303),每日3次,共39天,联合基于主动任务导向训练的标准化康复治疗。
- 统计分析于2024年11月至2025年8月进行。
主要发现
- 610例参与者中位(IQR)年龄73(64-82)岁,女性252例(41.3%),基线FMA总分中位(IQR)34(14-54)分。
- 至3个月时28例参与者死亡,582例(95.4%)参与者符合主要分析条件。
- 3个月时FMA总分中位(IQR)左旋多巴组68(42-85)分,安慰剂组64(44-83)分。
- 左旋多巴组与安慰剂组FMA总分平均差异为-0.90分(95%CI,-3.78至1.98;P=0.54)。
- 严重不良事件左旋多巴组126例,安慰剂组129例;最常见为感染(左旋多巴组55例,安慰剂组44例)。
关键数值与推荐
- 主要结局为3个月时FMA总分(范围0-100分,分越低运动功能越差,6分差异被认为具有患者相关性)的校正组间平均差异。
- FMA总分平均差异为-0.90分(95%CI,-3.78至1.98;P=0.54),未达统计学显著。
临床怎么用
- 原文结论指出,这些结果不支持使用左旋多巴作为康复治疗的辅助手段以增强急性卒中后运动恢复。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Levodopa enhances dopaminergic signaling and may stimulate neuroplasticity, which could potentially enhance motor recovery after stroke. Levodopa is used in stroke rehabilitation despite mixed evidence for its effectiveness. OBJECTIVE: To determine whether levodopa compared with placebo, administered in addition to standardized rehabilitation based on active task-oriented training, is associated with enhanced motor recovery in patients with acute stroke. DESIGN, SETTING, AND PARTICIPANTS: A double-blind, placebo-controlled randomized clinical trial at 13 stroke units and centers and 11 collaborating rehabilitation centers in Switzerland. Between June 14, 2019 (first patient, first visit), and August 27, 2024 (last patient, last visit), 610 patients with acute ischemic or hemorrhagic stroke with clinically meaningful hemiparesis (ie, a total score of ≥3 points on the following National Institutes of Health Stroke Scale items: motor arm, motor leg, or limb ataxia) were randomized 1:1 to receive levodopa or placebo. Statistical analyses were conducted from November 2024 to August 2025. INTERVENTION: Patients received levodopa/carbidopa (100 mg/25 mg; n = 307) or placebo (n = 303) 3 times daily for 39 days, alongside standardized rehabilitation therapy based on active task-oriented training. MAIN OUTCOMES AND MEASURES: The primary outcome was the adjusted mean between-group difference in the Fugl-Meyer Assessment (FMA) total score (range, 0-100 points; fewer points indicate worse motor function; 6-point difference considered patient-relevant) at 3 months. RESULTS: Among the 610 participants (median [IQR] age, 73 [64-82] years; 252 [41.3%] female; median baseline FMA total score, 34 [14-54]), 28 participants died by 3 months, leaving 582 (95.4%) participants eligible for the primary analysis. At 3 months, the median (IQR) FMA total score was 68 (42-85) points in the levodopa group and 64 (44-83) points in the placebo group. The mean difference in the FMA total score between the levodopa and placebo groups was -0.90 points (95% CI, -3.78 to 1.98; P = .54). There were 126 serious adverse events in the levodopa group and 129 in the placebo group; the most common was infection (levodopa, n = 55; placebo, n = 44). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, among patients receiving inpatient rehabilitation for acute stroke, levodopa added to standardized rehabilitation did not significantly improve motor function at 3 months compared with placebo plus standardized rehabilitation. These results do not support the use of levodopa as an adjunct to rehabilitation therapy for enhancing motor recovery after acute stroke. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03735901.
引用
- Engelter ST, Kaufmann JE, Zietz A, et al. Levodopa Added to Stroke Rehabilitation: The ESTREL Randomized Clinical Trial. JAMA. 2025. PMID: 40982270. doi:10.1001/jama.2025.15185
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。